ストックスクリーナーアプリを入手
15.02
2.34%
-0.36
アフターアワーズ：
15.02
前日終値:
$15.38
開ける：
$15.26
24時間の取引高:
1.89M
Relative Volume:
1.10
時価総額：
$1.33B
収益：
$203.45M
当期純損益:
$-351.45M
株価収益率:
-3.3011
EPS:
-4.55
ネットキャッシュフロー:
$-369.41M
1週間 パフォーマンス:
-5.18%
1か月 パフォーマンス:
-25.20%
6か月 パフォーマンス:
-20.15%
1年 パフォーマンス:
+113.96%
1日の値動き範囲:
$14.75
$15.40
1週間の範囲:
$14.75
$16.30
52週間の値動き範囲:
$6.80
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
名前
Travere Therapeutics Inc
セクター
電話
888-969-7879
住所
3611 VALLEY CENTRE DR, SAN DIEGO
TVTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
15.02 | 1.41B | 203.45M | -351.45M | -369.41M | -4.55 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-21 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-09 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-12-05 | アップグレード | Citigroup | Neutral → Buy |
| 2023-11-20 | 開始されました | Citigroup | Neutral |
| 2023-09-22 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 再開されました | Evercore ISI | Outperform |
| 2023-07-21 | 開始されました | JP Morgan | Overweight |
| 2023-06-07 | 再開されました | Piper Sandler | Neutral |
| 2023-05-22 | 開始されました | TD Cowen | Outperform |
| 2023-05-05 | アップグレード | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-21 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-12-14 | 開始されました | Stifel | Hold |
| 2022-12-05 | 開始されました | Wells Fargo | Overweight |
| 2022-09-21 | 開始されました | Bryan Garnier | Sell |
| 2022-07-14 | 再開されました | Canaccord Genuity | Buy |
| 2022-03-31 | 開始されました | Piper Sandler | Overweight |
| 2022-02-28 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-26 | ダウングレード | Wedbush | Outperform → Neutral |
すべてを表示
Travere Therapeutics Inc (TVTX) 最新ニュース
Levi & Korsinsky Launches Fraud Investigation on Behalf of Travere Therapeutics, Inc. (TVTX) Shareholders - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Would Travere Therapeutics (NASDAQ:TVTX) Be Better Off With Less Debt? - simplywall.st
Lost Money on Travere Therapeutics, Inc. (TVTX)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.TVTX - FinancialContent
FILSPARI to Transform Kidney Disease Care with Its Revolutionary Treatment Approach | DelveInsight - The Malaysian Reserve
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Cystinuria Pipeline 2025: Groundbreaking Clinical - openPR.com
Where are the Opportunities in (TVTX) - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Ameriprise Financial Inc. Purchases 162,649 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
2025-05-23 | Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation | NDAQ:TVTX | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Connect - ACCESS Newswire
2025-05-20 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Connect | NDAQ:TVTX | Press Release - Stockhouse
Travere Therapeutics: Establishing A Position After Last Week's Selloff (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics’ SWOT analysis: stock outlook amid regulatory review By Investing.com - Investing.com Nigeria
Travere Therapeutics’ SWOT analysis: stock outlook amid regulatory review - Investing.com
Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down – Should You Sell? - Defense World
Travere Therapeutics (NASDAQ:TVTX) Earns Outperform Rating from Wedbush - Defense World
The Manufacturers Life Insurance Company Reduces Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Stifel maintains hold on Travere stock amid FDA review delay By Investing.com - Investing.com South Africa
Travere Therapeutics Holds Annual Meeting, Elects Directors - TipRanks
The Plot Twist That Caused IBD 50's 10th Seed To Plummet - Investor's Business Daily
Travere Therapeutics stock falls on FDA review setback By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) Receives Outperform Rating from Wedb - GuruFocus
Travere Therapeutics (TVTX) Moves Forward with FILSPARI FDA Review | TVTX Stock News - GuruFocus
Travere Therapeutics (TVTX) Receives Outperform Rating from Wedbush | TVTX Stock News - GuruFocus
Travere flops as FDA accepts Filspari sNDA but plans AdCom - The Pharma Letter
Travere Therapeutics (TVTX) Receives a Buy from Bank of America Securities - The Globe and Mail
IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why - inkl
Travere Therapeutics' FDA Application Accepted for Filspari in Rare Kidney Disease - marketscreener.com
Cantor Fitzgerald maintains overweight on Travere Therapeutics stock - Investing.com
Travere (TVTX) Shares Drop as FDA Declines Priority Review | TVT - GuruFocus
Travere Therapeutics (TVTX) Sees Buying Opportunity Amid Review Timeline News | TVTX Stock News - GuruFocus
Northern Trust Corp Has $13.14 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Travere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off Worries - NewsBreak: Local News & Alerts
Travere Therapeutics’ sNDA for FILSPARI accepted by FDA - Investing.com Nigeria
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS - BioSpace
Travere stock falls on FDA AdCom for Filspari approval (TVTX) - Seeking Alpha
Travere Therapeutics (TVTX) Moves Forward with FILSPARI FDA Revi - GuruFocus
Travere Therapeutics’ FDA Acceptance for FILSPARI Application - TipRanks
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS | TVTX Stock News - GuruFocus
(TVTX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Transcript : Travere Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News - GuruFocus
IgA Nephropathy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals - The Globe and Mail
Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Position Reduced by Price T Rowe Associates Inc. MD - Defense World
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2025 - BioSpace
Travere Therapeutics Inc (TVTX) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):